Drug Target Insights最新文献

筛选
英文 中文
Characterization and enhanced antibiofilm activity of Annona muricata extract in combination with fluconazole against Candida albicans. 番麻提取物联合氟康唑对白色念珠菌的抑菌活性研究。
IF 2
Drug Target Insights Pub Date : 2025-01-13 eCollection Date: 2025-01-01 DOI: 10.33393/dti.2025.3171
Abhay P Mishra, Masande Yalo, Jennifer Nambooze, Carolina H Pohl, Gabré Kemp, Lekgoana K Setsiba, Motlalepula G Matsabisa
{"title":"Characterization and enhanced antibiofilm activity of <i>Annona muricata</i> extract in combination with fluconazole against <i>Candida albicans</i>.","authors":"Abhay P Mishra, Masande Yalo, Jennifer Nambooze, Carolina H Pohl, Gabré Kemp, Lekgoana K Setsiba, Motlalepula G Matsabisa","doi":"10.33393/dti.2025.3171","DOIUrl":"https://doi.org/10.33393/dti.2025.3171","url":null,"abstract":"<p><strong>Introduction: </strong><i>Candida albicans</i> biofilm formation is a significant contributor to antifungal resistance, necessitating new treatment strategies. <i>Annona muricata</i> Lin., a traditional herbal remedy, has shown promise in combating microbial infections. The purpose of this study was to assess the antibiofilm activity of the methanol extract of <i>A. muricata</i> leaves alone or with the addition of fluconazole against <i>C. albicans</i>.</p><p><strong>Methods: </strong>Phytochemicals from the methanol extract were analyzed by LC-MS, the XTT assay was used for metabolic activity, and morphological characteristics were examined using scanning electron microscopy (SEM). Molecular docking screening of identified compounds in <i>A. muricata</i> methanol leaves extract against a Sap3 receptor (PDB: 2H6T) was also performed.</p><p><strong>Results: </strong>The LC-MS analysis detected 17 possible phytochemicals. The methanol extract showed a dose-dependent inhibition of biofilm formation, with maximum inhibition of ~60% observed at 240 μg/ml, and inhibition by fluconazole increased from 32% to 76% as the concentration increased from 15 to 240 μg/ml. The combination of <i>A. muricata</i> and fluconazole increased the inhibition significantly, from 74% to 78% at 15 μg/ml to 240 μg/mL, respectively. SEM of control and treated <i>C. albicans</i> biofilms showed an altered morphology and loss of cell integrity by the combination, corroborating the findings. Plant phytochemicals also possess high binding affinity (-9.7 to 8.0 kcal/mol, respectively) for the Sap3 enzyme and may therefore have therapeutic potential against <i>C. albicans</i>.</p><p><strong>Conclusion: </strong>Consequently, the findings indicate that compounds in the <i>A. muricata</i> methanol extract may function in concert with fluconazole at sub-inhibitory concentrations to suppress <i>C. albicans</i> biofilm formation. This finding paves the way for the formulation and development of antifungal treatment regimens that may limit the development of fluconazole resistance employing this plant part.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"19 ","pages":"1-10"},"PeriodicalIF":2.0,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison. 意大利新生血管性老年黄斑变性法瑞昔单抗与标准疗法的比较:间接治疗比较。
IF 2
Drug Target Insights Pub Date : 2024-12-12 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.3213
Carlotta Galeone, Federica Turati, Massimo Nicolò, Mariacristina Parravano, Stela Vujosevic, Laura Bianchino, Emilia Sicari, Paolo Lanzetta
{"title":"Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison.","authors":"Carlotta Galeone, Federica Turati, Massimo Nicolò, Mariacristina Parravano, Stela Vujosevic, Laura Bianchino, Emilia Sicari, Paolo Lanzetta","doi":"10.33393/dti.2024.3213","DOIUrl":"10.33393/dti.2024.3213","url":null,"abstract":"<p><strong>Objectives: </strong>To assess through an indirect treatment comparison (ITC) the potential benefit of faricimab over the anti-vascular endothelial growth factor (VEGF) real-life scenario, hereby defined standard of care (SoC), in Italy, that is, aflibercept, bevacizumab, and ranibizumab, in patients with neovascular age-related macular degeneration (nAMD) naïve to any anti-VEGF treatment.</p><p><strong>Methods: </strong>Individual patient-level data from the phase III clinical trials TENAYA and LUCERNE (faricimab cohort) and the real-world study RADIANCE (RADIANCE cohort) were used. Efficacy was evaluated with changes in best corrected visual acuity (BCVA) and central subfield thickness (CST) from baseline to 1 year (week 52 in the RADIANCE and week 48 in the faricimab cohorts, respectively). Propensity score-based inverse probability of treatment weighting was utilized to balance cohorts and mitigate bias due to potential confounding. Sensitivity analyses were performed to evaluate treatment differences adjusted for the number of injections.</p><p><strong>Results: </strong>The ITC included 513 patients treated with faricimab and 263 patients treated with SoC. At 1 year, faricimab showed a greater mean BCVA gain (treatment difference +5.4 letters, p<0.001) and CST reduction (treatment difference -71.8 μm, p<0.001) compared to SoC. Sensitivity analyses confirmed the robustness of results, showing a BCVA improvement of +4.0 letters and a CST reduction of -71.5 μm in favor of faricimab.</p><p><strong>Conclusions: </strong>Despite the limitations due to the use of ITC and the comparison between clinical trials and real-world cohorts, the present analysis suggests potential benefits in terms of vision gain and CST reduction in naïve nAMD patients treated with faricimab compared with SoC in a real-world setting.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"105-111"},"PeriodicalIF":2.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the combinatory effect of Sclerocarya birrea with doxorubicin against selected colorectal cancer cell lines. 研究 Sclerocarya birrea 与多柔比星对特定结直肠癌细胞株的联合作用。
IF 2
Drug Target Insights Pub Date : 2024-12-11 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.3219
Thembelihle H Nxasana, Innocensia M Mangoato, Patriciah M Masiu, Abhay P Mishra, Motlalepula G Matsabisa
{"title":"Investigating the combinatory effect of <i>Sclerocarya birrea</i> with doxorubicin against selected colorectal cancer cell lines.","authors":"Thembelihle H Nxasana, Innocensia M Mangoato, Patriciah M Masiu, Abhay P Mishra, Motlalepula G Matsabisa","doi":"10.33393/dti.2024.3219","DOIUrl":"10.33393/dti.2024.3219","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer incidences continue to increase annually, worldwide. Herbal plants with antiproliferative properties received research interest as agents that can be adjuvant therapies with chemotherapy drugs to enhance their efficacy and reverse drug resistance.</p><p><strong>Methods: </strong><i>Sclerocarya birrea</i> ethanolic (SBE) and aqueous (SBW) extracts combined with doxorubicin (DOX) against drug-sensitive and drug-resistant colorectal cancer cells were investigated for their potential adjuvant and drug resistance reversal. The extracts were assessed for their potential anticancer activities on HCT15 and HT29 cell lines as well as their doxorubicin potentiating and drug resistance reversal effects respectively. The extracts were assessed for their cytotoxicity on normal 3T3-L1 fibroblast cells.</p><p><strong>Results: </strong>Both SBE and SBW extracts exhibited no toxicity against normal 3T3 cells and showed low activity on the HT29 cell line. Contrarily, resistant HCT15 cells showed moderate to low activity with significantly higher inhibitory concentration (IC)<sub>50</sub> values. The combination of SBE with DOX and SBW with DOX resulted in antagonistic interactions, causing an increase in IC<sub>50</sub> values for HT29 and HCT15 cells. In contrast, the combination of DOX and verapamil (VER) produced an additive effect, with no change in their IC<sub>50</sub> values.</p><p><strong>Conclusion: </strong>Based on the findings from the combination treatment, the SBE and SBW extracts demonstrated higher efficacy and synergistic effects combined with DOX at IC<sub>75</sub> compared to the combination of DOX and VER, suggesting their potential as anticancer agents. However, further research on both the SBE and SBW extracts' mechanisms of action and in vivo effects is warranted.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"94-104"},"PeriodicalIF":2.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytotoxic activity, selectivity, and clonogenicity of fruits and resins of Saudi medicinal plants against human liver adenocarcinoma. 沙特药用植物果实和树脂对人类肝腺癌的细胞毒活性、选择性和克隆性。
IF 2
Drug Target Insights Pub Date : 2024-10-22 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.3169
Ali Hendi Alghamdi, Aimun A E Ahmed, Mahadi Bashir, Haidar Abdalgadir, Asaad Khalid, Mohamed E Abdallah, Riyad Almaimani, Bassem Refaat, Ashraf N Abdalla
{"title":"Cytotoxic activity, selectivity, and clonogenicity of fruits and resins of Saudi medicinal plants against human liver adenocarcinoma.","authors":"Ali Hendi Alghamdi, Aimun A E Ahmed, Mahadi Bashir, Haidar Abdalgadir, Asaad Khalid, Mohamed E Abdallah, Riyad Almaimani, Bassem Refaat, Ashraf N Abdalla","doi":"10.33393/dti.2024.3169","DOIUrl":"https://doi.org/10.33393/dti.2024.3169","url":null,"abstract":"<p><strong>Background: </strong>Edible fruits and resins provide various benefits to mankind including potential medicinal applications. This study aimed to determine the cytotoxicity, selectivity, and clonogenicity of fruits and exudates of certain Saudi medicinal plants (<i>Anethum graveolens</i> (BEP-09), <i>Opuntia ficus-indica</i> (L.) Miller (BEP-10), <i>Boswellia serrata</i> Roxb. ex Colebr. (BEP-11), and <i>Commiphora myrrha</i> (BEP-12)) against human liver adenocarcinoma (HepG2).</p><p><strong>Methods: </strong>Initial cytotoxicity and cell line selectivity against different cell lines were screened using MTT assay. The most promising extract was subjected to gas chromatography-mass spectrometry (GC-MS) analysis to determine the main phytoconstituents. Clonogenicity was checked for the most active extract.</p><p><strong>Results: </strong>The selected plants' fruits and resins possess a significant cytotoxic activity estimated as IC<sub>50</sub>. The fruit of BEP-10 was found to be the most active extract against liver cancer cells (IC<sub>50</sub> = 2.82) comparable to both doxorubicin (IC<sub>50</sub> = 1.40) and camptothecin (IC<sub>50</sub> = 1.11). It showed a selectivity index of 4.47 compared to the normal human foetal lung fibroblast (MRC5) cells. BEP-10 showed a dose-dependent clonogenic effect against HepG2 cells comparable to the effect of doxorubicin. The GC-MS chromatogram of BEP-10 extract revealed the presence of eight small polar molecules, representing 73% of the total identified compounds and the rest three molecules (27%) were non-polar constituents. The furan derivatives represent the chief components in BEP-10 (16.3%), while the aldehyde 5-(hydroxymethyl)-2-furancarboxaldehyde was found to be the main molecule (13.2%).</p><p><strong>Conclusion: </strong>The fruits of BEP-10 have a potential cytotoxic effect particularly against HepG2. The identified phytoconstituents in the tested plant extract might contribute to the investigated cytotoxic activity.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"84-93"},"PeriodicalIF":2.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Levofloxacin induces erythrocyte contraction leading to red cell death. 左氧氟沙星可诱导红细胞收缩,导致红细胞死亡。
IF 2
Drug Target Insights Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.3060
Hafiz Muhammad Aslam, Azka Sohail, Ammara Shahid, Maham Abdul Bari Khan, Muhammad Umar Sharif, Razia Kausar, Samia Nawab, Waqas Farooq, Kashif Jilani, Majeeda Rasheed
{"title":"Levofloxacin induces erythrocyte contraction leading to red cell death.","authors":"Hafiz Muhammad Aslam, Azka Sohail, Ammara Shahid, Maham Abdul Bari Khan, Muhammad Umar Sharif, Razia Kausar, Samia Nawab, Waqas Farooq, Kashif Jilani, Majeeda Rasheed","doi":"10.33393/dti.2024.3060","DOIUrl":"10.33393/dti.2024.3060","url":null,"abstract":"<p><strong>Background: </strong>Levofloxacin, a fluoroquinolone, is an extensively used antibiotic effective against both positively and negatively staining bacteria. It works by inhibiting bacterial topoisomerase type II and topoisomerase type IV, resulting in impaired DNA synthesis and bacterial cell death. Eryptosis is another term for apoptotic cell death of erythrocyte marked by cell shrinkage, phosphatidylserine (PS) flipping, and membrane blebbing.</p><p><strong>Methods: </strong>The intent of the present research was to look at the eryptotic effect of levofloxacin by exposing erythrocytes to therapeutical doses (7, 14 µM) of levofloxacin for 48 hours. Cell size evaluation, PS subjection to outside, and calcium channel inhibition were carried out to investigate eryptosis. Oxidative stress generated by levofloxacin was measured as a putative mechanism of eryptosis using glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase activities. Similarly, hemolysis measurements demonstrated levofloxacin's cytotoxic effect.</p><p><strong>Results: </strong>Our findings showed that therapeutic doses of levofloxacin can cause a considerable decline in antioxidant enzymes activities, as well as induce cell shrinkage, PS externalization, and hemolysis in erythrocytes. The role of calcium in triggering erythrocyte shrinkage was also confirmed.</p><p><strong>Conclusion: </strong>In conclusion, our findings showed that the indicated levofloxacin doses caused oxidative stress, which leads to erythrocyte death via eryptosis and hemolysis. These findings emphasize the importance of using levofloxacin with caution and the need for additional research to mitigate these side effects.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"78-83"},"PeriodicalIF":2.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancement of apoptosis in Caco-2, Hep-G2, and HT29 cancer cell lines following exposure to Toxoplasma gondii peptides. 接触弓形虫肽后,Caco-2、Hep-G2 和 HT29 癌细胞系的细胞凋亡增强。
IF 2
Drug Target Insights Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.3177
Firooz Shahrivar, Javid Sadraei, Majid Pirestani, Ehsan Ahmadpour
{"title":"Enhancement of apoptosis in Caco-2, Hep-G2, and HT29 cancer cell lines following exposure to <i>Toxoplasma gondii</i> peptides.","authors":"Firooz Shahrivar, Javid Sadraei, Majid Pirestani, Ehsan Ahmadpour","doi":"10.33393/dti.2024.3177","DOIUrl":"10.33393/dti.2024.3177","url":null,"abstract":"<p><strong>Objective: </strong>Cancer or neoplasm is a cosmopolitan catastrophe that results in more than 20 million new cases and 10 million deaths every year. Some factors lead to carcinogenesis like infectious diseases. Parasites like <i>Toxoplasma gondii</i>, by its components, could modulate the cancer system by inducing apoptosis. The objective of this investigation is to assess the potential of peptides derived from <i>T. gondii</i> in combating cancer by examining their effects on Caco-2, Hep-G2, and HT29 cell lines.</p><p><strong>Materials and methods: </strong>Candidate peptide by its similarity to anticancer compounds was predicted through the computer-based analysis/platform. The impact of the peptide on cell viability, cell proliferation, and gene expression was evaluated through the utilization of MTT assay, flow cytometry, and real-time polymerase chain reaction (PCR) methodologies.</p><p><strong>Results: </strong>The cell viability rate exhibited a significant decrease (p < 0.001) across all cell lines when exposed to a concentration of ≤160 μg. Within the 48-hour timeframe, the half maximal inhibitory concentration (IC<sub>50</sub>) for HT29 and Hep-G2 cell lines was determined to be 107.2 and 140.6 μg/mL, respectively. Notably, a marked decrease in the expression levels of <i>Bcl2</i> and <i>APAF1</i> genes was observed in both the Hep-G2 and HT29 cell lines.</p><p><strong>Conclusion: </strong>These findings indicate that the <i>T. gondii</i> peptide affected cancer cell mortality and led to changes in the expression of genes associated with apoptosis.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"70-77"},"PeriodicalIF":2.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deciphering the molecular mechanisms underlying anti-pathogenic potential of a polyherbal formulation Enteropan® against multidrug-resistant Pseudomonas aeruginosa. 破译多草药配方 Enteropan® 针对耐多药铜绿假单胞菌抗病原潜力的分子机制。
IF 2
Drug Target Insights Pub Date : 2024-08-30 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.3082
Sweety Parmar, Gemini Gajera, Nidhi Thakkar, Hanmanthrao S Palep, Vijay Kothari
{"title":"Deciphering the molecular mechanisms underlying anti-pathogenic potential of a polyherbal formulation Enteropan® against multidrug-resistant <i>Pseudomonas aeruginosa</i>.","authors":"Sweety Parmar, Gemini Gajera, Nidhi Thakkar, Hanmanthrao S Palep, Vijay Kothari","doi":"10.33393/dti.2024.3082","DOIUrl":"10.33393/dti.2024.3082","url":null,"abstract":"<p><strong>Objective: </strong>Anti-pathogenic potential of a polyherbal formulation Enteropan® was investigated against a multidrug-resistant strain of the bacterium <i>Pseudomonas aeruginosa</i>.</p><p><strong>Methods: </strong>Growth, pigment production, antibiotic susceptibility, etc., were assessed through appropriate <i>in vitro</i> assays. Virulence of the test pathogen was assessed employing the nematode worm <i>Caenorhabditis elegans</i> as a model host. Molecular mechanisms underlining the anti-pathogenic activity of the test formulation were elucidated through whole transcriptome analysis of the extract-exposed bacterial culture.</p><p><strong>Results: </strong>Enteropan-pre-exposed <i>P. aeruginosa</i> displayed reduced (~70%↓) virulence towards the model host <i>C. elegans</i>. Enteropan affected various traits like biofilm formation, protein synthesis and secretion, quorum-modulated pigment production, antibiotic susceptibility, nitrogen metabolism, etc., in this pathogen. <i>P. aeruginosa</i> could not develop complete resistance to the virulence-attenuating activity of Enteropan even after repeated exposure to this polyherbal formulation. Whole transcriptome analysis showed 17% of <i>P. aeruginosa</i> genome to get differentially expressed under influence of Enteropan. Major mechanisms through which Enteropan exerted its anti-virulence activity were found to be generation of nitrosative stress, oxidative stress, envelop stress, quorum modulation, disturbance of protein homeostasis and metal homeostasis. Network analysis of the differently expressed genes resulted in identification of 10 proteins with high network centrality as potential targets from among the downregulated genes. Differential expression of genes coding for five (<i>rpoA</i>, <i>tig</i>, <i>rpsB</i>, <i>rpsL</i>, and <i>rpsJ</i>) of these targets was validated through real-time polymerase chain reaction too, and they can further be pursued as potential targets by various drug discovery programmes.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"54-69"},"PeriodicalIF":2.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vivo analgesic, anti-inflammatory, sedative, muscle relaxant activities, and docking studies of 3',4',7,8-tetrahydroxy-3-methoxyflavone isolated from Pistacia chinensis. 从Pistacia chinensis 中分离的 3',4',7,8-四羟基-3-甲氧基黄酮的体内镇痛、抗炎、镇静和肌肉松弛活性及对接研究。
IF 2
Drug Target Insights Pub Date : 2024-06-18 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.2745
Abdur Rauf, Umer Rashid, Najla Al Masoud, Zuneera Akram, Anees Saeed, Naveed Muhammad, Taghrid S Alomar, Saima Naz, Marcello Iriti
{"title":"In vivo analgesic, anti-inflammatory, sedative, muscle relaxant activities, and docking studies of 3',4',7,8-tetrahydroxy-3-methoxyflavone isolated from <i>Pistacia chinensis</i>.","authors":"Abdur Rauf, Umer Rashid, Najla Al Masoud, Zuneera Akram, Anees Saeed, Naveed Muhammad, Taghrid S Alomar, Saima Naz, Marcello Iriti","doi":"10.33393/dti.2024.2745","DOIUrl":"10.33393/dti.2024.2745","url":null,"abstract":"<p><strong>Background: </strong><i>Pistacia chinensis</i> is extensively employed in traditional medicine. This study aimed to isolate and evaluate the therapeutic effects of 3'4'78-tetrahydroxy-3-methoxyflavone from <i>P. chinensis</i> crude extract.</p><p><strong>Materials and methods: </strong>The study utilized column chromatography for isolation. The plant extract and its isolated compound were assessed for in vivo analgesic (hot plate model), anti-inflammatory (carrageenan-induced paw edema), sedative (open field model), and muscle relaxing properties (inclined plane and traction test).</p><p><strong>Results: </strong>In the thermal-induced analgesic model, a significant analgesic effect was observed for the extract (25, 50, and 100 mg/kg) and the isolated compound (2.5, 5, 10, and 15 mg/kg) at higher doses. The extract (100 mg/kg) significantly prolonged latency time (21.98 seconds) after 120 minutes of administration. The isolated compound elevated the latency time (20.03 seconds) after 30 minutes, remaining significant up to 120 minutes with a latency time of 24.11 seconds. The anti-inflammatory effect showed a reduction in inflammatory reactions by 50.23% (extract) and 67.09% (compound) after the fifth hour of treatment. Both samples demonstrated significant sedative effects, with the extract hindering movement by 54.11 lines crossed compared to the negative control (180.99 lines). The isolated compound reduced the number of lines crossed to 15.23±SEM compared to the negative control. Both samples were also significant muscle relaxants. Docking studies indicated that the compound's therapeutic effect is due to inhibiting COX and nociceptive pathways.</p><p><strong>Conclusion: </strong>The isolated compound from <i>Pistacia chinensis</i> exhibits significant analgesic, anti-inflammatory, sedative, and muscle relaxing properties, with potential therapeutic applications by inhibiting COX and nociceptive pathways.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"47-53"},"PeriodicalIF":2.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11188735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular targets and therapeutic potential of baicalein: a review. 黄芩苷的分子靶点和治疗潜力:综述。
IF 2.7
Drug Target Insights Pub Date : 2024-06-06 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.2707
Kavita Munjal, Yash Goel, Vinod Kumar Gauttam, Hitesh Chopra, Madhav Singla, Smriti, Saurabh Gupta, Rohit Sharma
{"title":"Molecular targets and therapeutic potential of baicalein: a review.","authors":"Kavita Munjal, Yash Goel, Vinod Kumar Gauttam, Hitesh Chopra, Madhav Singla, Smriti, Saurabh Gupta, Rohit Sharma","doi":"10.33393/dti.2024.2707","DOIUrl":"10.33393/dti.2024.2707","url":null,"abstract":"<p><strong>Aim: </strong>Researchers using herbs and natural products to find new drugs often prefer flavonoids because of their potential as antioxidants and anti-inflammatories. The planned review addressed baicalein research findings in detail. This manuscript provides a complete review of baicalein's potential pharmacological effects along with several molecular targets for better understanding of its therapeutic activities.</p><p><strong>Materials and methods: </strong>We targeted the review on in vitro and in vivo studies reported on baicalein. For this, the literature is gathered from the database available on search engines like PubMed, ScienceDirect, Scopus, and Google Scholar up to 21 December 2023. The keywords \"<i>Scutellaria baicalensis</i>\", \"<i>Oroxylum indicum</i>\", \"<i>Neuroprotective</i>\", \"<i>Cardioprotective</i>\", \"<i>Toxicity studies</i>\", and \"<i>Baicalein</i>\" were used to fetch the content.</p><p><strong>Results: </strong>Baicalein's molecular receptor binding approach has shown anticancer, antidiabetic, antimicrobial, antiaging, neuroprotective, cardioprotective, respiratory protective, gastroprotective, hepatic protective, and renal protective effects. The synergistic effects of this drug with other selective herbs are also contributed towards significant therapeutic potential.</p><p><strong>Conclusion: </strong>This systematic review article from a contemporary and scientific perspective offers fresh insight into <i>S. baicalensis</i>, <i>O. indicum</i>, and its bioactive component baicalein as a potential complementary medicine. Baicalein may be transformed into more efficacious and acceptable evidence-based medicine. However, we recommend more clinical and mechanistic approaches to confirm safety and efficacy of baicalein.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"30-46"},"PeriodicalIF":2.7,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11168303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients. K417、E484和N501残基的RBD突变降低了疫苗接种者和COVID-19康复者抗血清的免疫反应性。
IF 2.7
Drug Target Insights Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.33393/dti.2024.3059
Dablu Lal Gupta, Jhasketan Meher, Anjan Kumar Giri, Arvind K Shukla, Eli Mohapatra, Manisha M Ruikar, D N Rao
{"title":"RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients.","authors":"Dablu Lal Gupta, Jhasketan Meher, Anjan Kumar Giri, Arvind K Shukla, Eli Mohapatra, Manisha M Ruikar, D N Rao","doi":"10.33393/dti.2024.3059","DOIUrl":"10.33393/dti.2024.3059","url":null,"abstract":"<p><strong>Introduction: </strong>It is unclear whether induced spike protein-specific antibodies due to infections with SARS-CoV-2 or to the prototypic Wuhan isolate-based vaccination can immune-react with the emerging variants of SARS-CoV-2.</p><p><strong>Aim/objectives: </strong>The main objective of the study was to measure the immunoreactivity of induced antibodies postvaccination with Covishield™ (ChAdOx1 nCoV-19 coronavirus vaccines) or infections with SARS-CoV-2 by using selected peptides of the spike protein of wild type and variants of SARS-CoV-2.</p><p><strong>Methodology: </strong>Thirty patients who had recovered from SARS-CoV-2 infections and 30 individuals vaccinated with both doses of Covishield™ were recruited for the study. Venous blood samples (5 mL) were collected at a single time point from patients within 3-4 weeks of recovery from SARS-CoV-2 infections or receiving both doses of Covishield™ vaccines. The serum levels of total immunoglobulin were measured in both study groups. A total of 12 peptides of 10 to 24 amino acids length spanning to the receptor-binding domain (RBD) of wild type of SARS-CoV-2 and their variants were synthesized. The serum levels of immune-reactive antibodies were measured using these peptides.</p><p><strong>Results: </strong>The serum levels of total antibodies were found to be significantly (p<0.001) higher in the vaccinated individuals as compared to COVID-19 recovered patients. Our study reported that the mutations in the RBD at the residues K417, E484, and N501 have been associated with reduced immunoreactivity with anti-sera of vaccinated people and COVID-19 recovered patients.</p><p><strong>Conclusion: </strong>The amino acid substitutions at the RBD of SARS-CoV-2 have been associated with a higher potential to escape the humoral immune response.</p>","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"18 ","pages":"20-26"},"PeriodicalIF":2.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11163369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信